Selma Tekin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Selma Tekin has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Levent Sinan Bir
Neurology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
4 shared publications - Ahmet Küçük
University of Health Sciences, Konya Beyhekim Training and Research Hospital, Neurology Clinic, Konya, Türkiye
2 shared publications - Ahmet Magrur Karagulmez
Department of Neurology, Servergazi State Hospital, Denizli, Turkey
2 shared publications - Ahmet Yusuf Ertürk
Department of Neurology, Division of Clinical Neurophysiology, University of Health Sciences Adana City Training and Research Hospital, Adana, Türkiye
2 shared publications - Aylin Bican Demir
Bursa Uludag University, Medical Faculty, Department of Neurology, Bursa, Türkiye
2 shared publications - Ayşegül Şeyma Sarıtaş
Department of Neurology, Celal Bayar University, Manisa, Turkey
2 shared publications
Latest Publications
- 9 September 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 766
Exploring the Type 4 Cerebrospinal Fluid Oligoclonal Band Pattern: Clinical and Paraclinical Features with Diagnostic Implications
- 9 September 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 766
Exploring the Type 4 Cerebrospinal Fluid Oligoclonal Band Pattern: Clinical and Paraclinical Features with Diagnostic Implications
- Open Access
- 28 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (35) , e50425
Serum amylin levels in patients with multiple sclerosis
Amylin is a pancreatic neuroendocrine peptide that links peripheral metabolic regulation with central homeostatic and neurodegenerative pathways. However, its relevance to the inflammatory and demyelinating processes underlying multiple sclerosis (MS) remains unclear. To date, the role of amylin in MS has not been investigated. This study investigated serum amylin levels in patients with MS and their association with disease status. This cross-sectional case-control study included 62 patients meeting the 2017 McDonald criteria for MS and 63 control participants without MS or associated risk factors. Serum amylin levels were measured using enzyme-linked immunosorbent assay (ELISA). Between-group and phenotype-specific differences were examined. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess the association between serum amylin and MS status, and the discriminatory performance of serum amylin, respectively. Serum amylin levels were determined in both groups and reported as mean values. Mean serum amylin levels were significantly lower in patients with MS than in controls (234.01 ± 94.84 vs 284.04 ± 110.02 ng/L; P = .003). The groups were comparable across the principal anthropometric, metabolic, and biochemical variables assessed. No significant differences were observed among the relapsing–remitting, secondary progressive, and primary progressive MS (PPMS) phenotypes; however, pairwise analysis demonstrated a significant difference between the relapsing–remitting MS (RRMS) subgroup and controls ( P = .017). In multivariable analysis, higher serum amylin levels remained independently associated with lower odds of MS after adjustment for aspartate aminotransferase (AST) activity ( P = .02). Despite the significant between-group difference, serum amylin demonstrated only modest discriminatory performance ( P = .003). Lower circulating amylin levels were associated with MS status, although their modest discriminatory performance does not support the use of serum amylin as a standalone diagnostic marker, based on the present data. The phenotype-specific difference observed in RRMS warrants further investigation in larger, longitudinal, and clinically characterized cohorts. These findings may deepen insights into MS development and support future biomarker research.
- 28 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (35) , e50425
Open AccessSerum amylin levels in patients with multiple sclerosis
Amylin is a pancreatic neuroendocrine peptide that links peripheral metabolic regulation with central homeostatic and neurodegenerative pathways. However, its relevance to the inflammatory and demyelinating processes underlying multiple sclerosis (MS) remains unclear. To date, the role of amylin in MS has not been investigated. This study investigated serum amylin levels in patients with MS and their association with disease status. This cross-sectional case-control study included 62 patients meeting the 2017 McDonald criteria for MS and 63 control participants without MS or associated risk factors. Serum amylin levels were measured using enzyme-linked immunosorbent assay (ELISA). Between-group and phenotype-specific differences were examined. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess the association between serum amylin and MS status, and the discriminatory performance of serum amylin, respectively. Serum amylin levels were determined in both groups and reported as mean values. Mean serum amylin levels were significantly lower in patients with MS than in controls (234.01 ± 94.84 vs 284.04 ± 110.02 ng/L; P = .003). The groups were comparable across the principal anthropometric, metabolic, and biochemical variables assessed. No significant differences were observed among the relapsing–remitting, secondary progressive, and primary progressive MS (PPMS) phenotypes; however, pairwise analysis demonstrated a significant difference between the relapsing–remitting MS (RRMS) subgroup and controls ( P = .017). In multivariable analysis, higher serum amylin levels remained independently associated with lower odds of MS after adjustment for aspartate aminotransferase (AST) activity ( P = .02). Despite the significant between-group difference, serum amylin demonstrated only modest discriminatory performance ( P = .003). Lower circulating amylin levels were associated with MS status, although their modest discriminatory performance does not support the use of serum amylin as a standalone diagnostic marker, based on the present data. The phenotype-specific difference observed in RRMS warrants further investigation in larger, longitudinal, and clinically characterized cohorts. These findings may deepen insights into MS development and support future biomarker research.
- Open Access
- 1 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (06) , 001-008
Innsbruck REM Sleep Behavior Disorder Inventory may distinguish abnormal nocturnal movements related to obstructive sleep apnea
Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by recurrent dream enactment behaviors like sleep-related vocalization and/or complex motor behaviors.To investigate the discriminative role of the validated Turkish version of the 9-Item Innsbruck REM Sleep Behavior Disorder Inventory (IRBD-9-Turkish) for idiopathic RBD (iRBD) in patients with obstructive sleep apnea (OSA).The current multicenter study was prospectively conducted in 13 accredited sleep centers in 10 different cities in Türkiye. Clinical data was obtained through a preformed questionnaire, and all participants were submitted to a full-night video-polysomnography (video-PSG) session in a sleep laboratory.A total of 105 patients (mean age: 58.3 ± 11.6 years; 68.6% of male subjects) were prospectively and consecutively enrolled in the study; 51 patients (48.6%) presented iRBD, and 54 (51.4%), OSA, 19 (35.2%) of whom presented abnormal nocturnal behaviors (NBs) demonstrated by clinical and video-PSG findings associated with arousal reactions secondary to apneas and hypopneas. The cut-off value of the IRBD-9 was higher in patients with OSA-NBs than in those with OSA without NBs (p < 0.001), with a sensitivity of 0.765 and a specificity of 0.667, resulting in a correct diagnosis of NBs in 75% of patients with OSA. The receiver operating characteristic (ROC) curves for Factor I (items 1, 2, 3, 6, and 8) and Factor II (items 4, 5, 7, and 9) of the IRBD-9-Turkish showed that both factors were able to distinguish patients with iRBD from those with OSA, but only Factor I distinguishes patients with iRBD from those with OSA-NBs.The present study demonstrated a very high sensitivity and specificity of the IRBD-9-Turkish not only in patients with iRBD, but also in patients with OSA.
- 1 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (06) , 001-008
Open AccessInnsbruck REM Sleep Behavior Disorder Inventory may distinguish abnormal nocturnal movements related to obstructive sleep apnea
Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by recurrent dream enactment behaviors like sleep-related vocalization and/or complex motor behaviors.To investigate the discriminative role of the validated Turkish version of the 9-Item Innsbruck REM Sleep Behavior Disorder Inventory (IRBD-9-Turkish) for idiopathic RBD (iRBD) in patients with obstructive sleep apnea (OSA).The current multicenter study was prospectively conducted in 13 accredited sleep centers in 10 different cities in Türkiye. Clinical data was obtained through a preformed questionnaire, and all participants were submitted to a full-night video-polysomnography (video-PSG) session in a sleep laboratory.A total of 105 patients (mean age: 58.3 ± 11.6 years; 68.6% of male subjects) were prospectively and consecutively enrolled in the study; 51 patients (48.6%) presented iRBD, and 54 (51.4%), OSA, 19 (35.2%) of whom presented abnormal nocturnal behaviors (NBs) demonstrated by clinical and video-PSG findings associated with arousal reactions secondary to apneas and hypopneas. The cut-off value of the IRBD-9 was higher in patients with OSA-NBs than in those with OSA without NBs (p < 0.001), with a sensitivity of 0.765 and a specificity of 0.667, resulting in a correct diagnosis of NBs in 75% of patients with OSA. The receiver operating characteristic (ROC) curves for Factor I (items 1, 2, 3, 6, and 8) and Factor II (items 4, 5, 7, and 9) of the IRBD-9-Turkish showed that both factors were able to distinguish patients with iRBD from those with OSA, but only Factor I distinguishes patients with iRBD from those with OSA-NBs.The present study demonstrated a very high sensitivity and specificity of the IRBD-9-Turkish not only in patients with iRBD, but also in patients with OSA.
- Open Access
- 15 January 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (01) , 001-007
Validity and reliability of the Turkish version of the Innsbruck RBD-9 diagnostic inventory (IRBD-9-TR)
Background Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by loss of the normal atonia of REM sleep accompanied by repetitive motor and behavior phenomena of dream content. Objective To evaluate the reliability and validity of the Turkish version of the original form of the Innsbruck Rapid Eye Movement Sleep Behavior Disorder Diagnostic Inventory (IRBD-9) scale (IRBD-9-TR) and ensure that this screening test can be easily used in the Turkish language. Methods The present is a multicenter and prospective study involving 184 patients: 51 with iRBD and 133 healthy controls. The iRBD patients were not diagnosed before submitted to video polysomnography (vPSG) and filling out the IRBD-9-TR. Results The optimal cut-off value for the IRBD-9-TR symptom score was of 0.28, with a sensitivity of 0.941 and a specificity of 0.947, and 94.4% of the patients were correctly diagnosed. The rotated factor loadings for the diagnostic accuracy of each individual question showed that the short version of the IRBD-9-TR (questions 1, 2, 3, 6, and 8) presented higher specificity and excellent discrimination of iRBD patients from healthy controls. The Cronbach's α coefficient for the symptom section of the IRBD-9-TR was of 0.857, and the Kappa coefficient, of 0.885. Conclusion The short version of the IRBD-9-TR presents good validity and reliability to be used as a screening test to assess iRBD patients. It is convenient and potentially useful in both outpatient clinical and epidemiologic research settings.
- 15 January 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (01) , 001-007
Open AccessValidity and reliability of the Turkish version of the Innsbruck RBD-9 diagnostic inventory (IRBD-9-TR)
Background Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by loss of the normal atonia of REM sleep accompanied by repetitive motor and behavior phenomena of dream content. Objective To evaluate the reliability and validity of the Turkish version of the original form of the Innsbruck Rapid Eye Movement Sleep Behavior Disorder Diagnostic Inventory (IRBD-9) scale (IRBD-9-TR) and ensure that this screening test can be easily used in the Turkish language. Methods The present is a multicenter and prospective study involving 184 patients: 51 with iRBD and 133 healthy controls. The iRBD patients were not diagnosed before submitted to video polysomnography (vPSG) and filling out the IRBD-9-TR. Results The optimal cut-off value for the IRBD-9-TR symptom score was of 0.28, with a sensitivity of 0.941 and a specificity of 0.947, and 94.4% of the patients were correctly diagnosed. The rotated factor loadings for the diagnostic accuracy of each individual question showed that the short version of the IRBD-9-TR (questions 1, 2, 3, 6, and 8) presented higher specificity and excellent discrimination of iRBD patients from healthy controls. The Cronbach's α coefficient for the symptom section of the IRBD-9-TR was of 0.857, and the Kappa coefficient, of 0.885. Conclusion The short version of the IRBD-9-TR presents good validity and reliability to be used as a screening test to assess iRBD patients. It is convenient and potentially useful in both outpatient clinical and epidemiologic research settings.
- Open Access
- 2 April 2024
- Published by Balikesir University in BALIKESIR HEALTH SCIENCES JOURNAL
- Vol. 13 (2) , 360-367
Anxiety Levels and Sleep Quality of Patients in Neurology Department during the Pandemic Process
Amaç: COVID-19, kısa zamanda tüm dünyayı etkisi altına alarak yaşam koşullarını çok büyük oranda etkilemiştir. Bu çalışmanın amacı pandemi sürecinde nörolojik hastalığı olup nöroloji servisinde yatan nöroloji hastalarının anksiyete düzeyi ve uyku kalitesini amacıyla yapılmıştır. Gereç ve Yöntem: Araştırma verileri 20 Mart -20 Mayıs 2021 tarihleri arasında yüzyüze soru-cevap olarak toplanmıştır. Araştırmaya, 100 ( 55 Kadın, 45 Erkek) hasta katılmıştır. Veri toplama aracı olarak uyku kalitesini değerlendirmek için Pittsburgh Uyku Kalitesi İndeksi (PUKİ), anksiyeteyi değerlendirmek için Koronavirüs anksiyete Ölçeği (KAÖ) kullanılmıştır. Bulgular: İki grubun anksiyete ölçeği puan ortalamaları, PUKİ total puan ortalamaları ve alt parametrelerinden uyku latansı, uyku süresi, uyku bozukluğu arasında anlamlı fark saptandı (p0,05). Anksiyete düzeyi ile uyku kalitesi arasında pozitif yönde orta düzey korelasyon olduğu görüldü (p=0,000, r=0,472). Anksiyete düzeyi ile uyku kalitesinin alt parametrelerinden öznel uyku kalitesi (p=0,000, r=0,439) ile pozitif yönde orta düzey anlamlı ilişki saptandı. Sonuç: Covid19 hastalığının bireylerin anksiyete düzeyi ve uyku kalitesi üzerinde olumsuz etkileri vardır. Bu etkilerin boyutları incelenmelidir. Ve tedavilerde bu etkilerin gözönünde bulundurularak yapılması önemlidir.
- 2 April 2024
- Published by Balikesir University in BALIKESIR HEALTH SCIENCES JOURNAL
- Vol. 13 (2) , 360-367
Open AccessAnxiety Levels and Sleep Quality of Patients in Neurology Department during the Pandemic Process
Amaç: COVID-19, kısa zamanda tüm dünyayı etkisi altına alarak yaşam koşullarını çok büyük oranda etkilemiştir. Bu çalışmanın amacı pandemi sürecinde nörolojik hastalığı olup nöroloji servisinde yatan nöroloji hastalarının anksiyete düzeyi ve uyku kalitesini amacıyla yapılmıştır. Gereç ve Yöntem: Araştırma verileri 20 Mart -20 Mayıs 2021 tarihleri arasında yüzyüze soru-cevap olarak toplanmıştır. Araştırmaya, 100 ( 55 Kadın, 45 Erkek) hasta katılmıştır. Veri toplama aracı olarak uyku kalitesini değerlendirmek için Pittsburgh Uyku Kalitesi İndeksi (PUKİ), anksiyeteyi değerlendirmek için Koronavirüs anksiyete Ölçeği (KAÖ) kullanılmıştır. Bulgular: İki grubun anksiyete ölçeği puan ortalamaları, PUKİ total puan ortalamaları ve alt parametrelerinden uyku latansı, uyku süresi, uyku bozukluğu arasında anlamlı fark saptandı (p0,05). Anksiyete düzeyi ile uyku kalitesi arasında pozitif yönde orta düzey korelasyon olduğu görüldü (p=0,000, r=0,472). Anksiyete düzeyi ile uyku kalitesinin alt parametrelerinden öznel uyku kalitesi (p=0,000, r=0,439) ile pozitif yönde orta düzey anlamlı ilişki saptandı. Sonuç: Covid19 hastalığının bireylerin anksiyete düzeyi ve uyku kalitesi üzerinde olumsuz etkileri vardır. Bu etkilerin boyutları incelenmelidir. Ve tedavilerde bu etkilerin gözönünde bulundurularak yapılması önemlidir.
- 22 December 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 150, 109568
The effect of sleep disorders on quality of life in patients with epilepsy: A multicenter study from Turkey
- 22 December 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 150, 109568
The effect of sleep disorders on quality of life in patients with epilepsy: A multicenter study from Turkey
- 15 December 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (4) , 386-391
The Effect of Sleep Disorders and Fatigue on In-vehicle Traffic Accidents
- 15 December 2022
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 10 (4) , 386-391
The Effect of Sleep Disorders and Fatigue on In-vehicle Traffic Accidents
- Open Access
- 17 October 2022
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 27 (4) , 251-256
Evaluation of cognitive dysfunction by the clock drawing test in multiple sclerosis and clinically isolated syndrome patients: Correlation with other neuropsychological tests
Objectives: To evaluate the cognitive status with a simple practical test, clock drawing test (CDT), in a larger multiple sclerosis (MS) patient group and in comparison, with controls. Methods: We included 171 patients (17–65 years) with MS and clinically isolated syndrome (CIS) and 98 healthy controls who applied between date 2018-2020 years in Neurology Department of Pamukkale University. The CDTs were applied to all subjects. In addition, the cognitive functions of the patient group were evaluated with the neuropsychological test battery. Results: The CDT scores were significantly lower in relapsing-remitting MS (RRMS) group than the control group (ppp<0.0001). Conclusion: The CDT cognitive impairment prediction performance is 60%, CDT is a useful, easy-to-administer, practical test that can be used in cognitive assessment in MS and CIS.
- 17 October 2022
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 27 (4) , 251-256
Open AccessEvaluation of cognitive dysfunction by the clock drawing test in multiple sclerosis and clinically isolated syndrome patients: Correlation with other neuropsychological tests
Objectives: To evaluate the cognitive status with a simple practical test, clock drawing test (CDT), in a larger multiple sclerosis (MS) patient group and in comparison, with controls. Methods: We included 171 patients (17–65 years) with MS and clinically isolated syndrome (CIS) and 98 healthy controls who applied between date 2018-2020 years in Neurology Department of Pamukkale University. The CDTs were applied to all subjects. In addition, the cognitive functions of the patient group were evaluated with the neuropsychological test battery. Results: The CDT scores were significantly lower in relapsing-remitting MS (RRMS) group than the control group (ppp<0.0001). Conclusion: The CDT cognitive impairment prediction performance is 60%, CDT is a useful, easy-to-administer, practical test that can be used in cognitive assessment in MS and CIS.
- Open Access
- 18 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26981
Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls
Multiple sclerosis (MS) is a major global problem, and as its pathogenesis is understood more clearly, therapeutic options expand accordingly. The mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) is a novel mitochondria-derived protein acting on metabolic homeostasis. In this study, we aimed to investigate the role of serum MOTS-c in the pathophysiology of the disease in MS patients and to discuss the mechanism of MOTS-c. In total, 43 patients diagnosed with relapsing-remitting MS and 41 healthy controls were enrolled in the study. MOTS-c, fasting blood glucose, insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), lipid panel, and body mass index levels were assessed. The participants’ MOTS-c levels remained significantly lower than that of the control group, while their fasting blood glucose and HOMA-IR values were higher. The multivariate logistic regression analysis established that increased MOTS-c levels could be a protective factor against the development of MS disease. The area under the receiver operating characteristic curve for MOTS-c was calculated as 0.782 (95% confidence interval = 0.684-0.879, p = 0.0001). This study is the first to scrutinize MOTS-c levels in MS patients. We tried to provide clinical evidence that MOTS-c could act as a highly discriminative biomarker between MS patients and control groups, which may hold great promise for future therapeutic options.
- 18 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26981
Open AccessComparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls
Multiple sclerosis (MS) is a major global problem, and as its pathogenesis is understood more clearly, therapeutic options expand accordingly. The mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) is a novel mitochondria-derived protein acting on metabolic homeostasis. In this study, we aimed to investigate the role of serum MOTS-c in the pathophysiology of the disease in MS patients and to discuss the mechanism of MOTS-c. In total, 43 patients diagnosed with relapsing-remitting MS and 41 healthy controls were enrolled in the study. MOTS-c, fasting blood glucose, insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), lipid panel, and body mass index levels were assessed. The participants’ MOTS-c levels remained significantly lower than that of the control group, while their fasting blood glucose and HOMA-IR values were higher. The multivariate logistic regression analysis established that increased MOTS-c levels could be a protective factor against the development of MS disease. The area under the receiver operating characteristic curve for MOTS-c was calculated as 0.782 (95% confidence interval = 0.684-0.879, p = 0.0001). This study is the first to scrutinize MOTS-c levels in MS patients. We tried to provide clinical evidence that MOTS-c could act as a highly discriminative biomarker between MS patients and control groups, which may hold great promise for future therapeutic options.
- 11 April 2022
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 43 (3) , 281-288
Serum 25(OH) vitamin D level in Relapsing-Remitting Multiple Sclerosis and clinically isolated syndrome groups
Objectives: Vitamin D is an important regulator of the immune system, and it has been shown that deficiency of vitamin D is significant environmental factor in some immune-mediated diseases such as Multiple Sclerosis (MS). In this study, we have compared serum 25 hydroxyvitamin (OH) D levels in Relapsing-Remitting Multiple Sclerosis (RRMS), clinically isolated syndrome (CIS), and control groups. Methods: Forty patients with CIS and 60 patients who have been diagnosed RRMS between age 18–45, respectively, and followed up at Pamukkale University Faculty of Medicine, Department of Neurology, and 60 healthy individuals have been included in this study. Serum 25(OH) vitamin D, calcium, phosphorus, alkaline phosphatase, parathormone, insulin, and fasting blood glucose levels were studied for all three groups. Results: A statistically significant difference was determined in the comparison of three groups for mean 25(OH) vitamin D levels. In the intergroup comparison of mean 25(OH) vitamin D; mean 25(OH) vitamin D level was determined to be statistically significantly lower in both RRMS and CIS groups compared to control group (p<0.05). Conclusions: Since vitamin D deficiency poses a problem from the early stage of disease spectrum in both CIS patients and MS patients, 25(OH) vitamin D level should be routinely controlled, and replacement should be administered upon any deficiency state.
- 11 April 2022
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 43 (3) , 281-288
Serum 25(OH) vitamin D level in Relapsing-Remitting Multiple Sclerosis and clinically isolated syndrome groups
Objectives: Vitamin D is an important regulator of the immune system, and it has been shown that deficiency of vitamin D is significant environmental factor in some immune-mediated diseases such as Multiple Sclerosis (MS). In this study, we have compared serum 25 hydroxyvitamin (OH) D levels in Relapsing-Remitting Multiple Sclerosis (RRMS), clinically isolated syndrome (CIS), and control groups. Methods: Forty patients with CIS and 60 patients who have been diagnosed RRMS between age 18–45, respectively, and followed up at Pamukkale University Faculty of Medicine, Department of Neurology, and 60 healthy individuals have been included in this study. Serum 25(OH) vitamin D, calcium, phosphorus, alkaline phosphatase, parathormone, insulin, and fasting blood glucose levels were studied for all three groups. Results: A statistically significant difference was determined in the comparison of three groups for mean 25(OH) vitamin D levels. In the intergroup comparison of mean 25(OH) vitamin D; mean 25(OH) vitamin D level was determined to be statistically significantly lower in both RRMS and CIS groups compared to control group (p<0.05). Conclusions: Since vitamin D deficiency poses a problem from the early stage of disease spectrum in both CIS patients and MS patients, 25(OH) vitamin D level should be routinely controlled, and replacement should be administered upon any deficiency state.